Immix Biopharma (IMMX) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $19.00 from $20.00 | Aug 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 from $20.00 | Aug 10, 2026 |
| Needham | Initiated Coverage | Buy | $21.00 | Jul 22, 2026 |
| B of A Securities | Initiated Coverage | Buy | $27.00 | Jun 18, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $19.00 | Jun 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $15.00 | May 22, 2026 |
| Mizuho | Maintained | Outperform | $15.00 from $14.00 | Mar 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 | Mar 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $12.00 | Mar 27, 2026 |
| Citizens | Maintained | Market Outperform | $23.00 | Mar 27, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $20.00 | Mar 25, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $23.00 | Mar 9, 2026 |
| Mizuho | Initiated Coverage | Outperform | $14.00 | Feb 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 from $8.00 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 from $7.00 | Sep 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Jun 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Feb 10, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Jan 6, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Oct 3, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Aug 19, 2024 |
Frequently asked questions
What is the price target for IMMX stock?
The average 12-month analyst price target for Immix Biopharma (IMMX) is $22.20, with a high estimate of $27.00 and a low of $19.00, across 5 analysts.
Is IMMX a buy, sell, or hold?
Analysts covering Immix Biopharma currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for IMMX?
The average price target of $22.20 implies 60.17% upside from the last price of $13.86.
What is the latest analyst rating on IMMX?
On Aug 11, 2026, Morgan Stanley maintained Immix Biopharma at Overweight with a price target of $19.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.